Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron
emission tomography (PET) and single-photon imaging, including single-photon emission …

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor
(VEGFR) are two extensively studied membrane-bound receptor tyrosine kinase proteins …

Imaging of expression of therapeutic targets may enable stratification of patients for targeted
treatments. The use of small radiolabeled probes based on the heavy-chain variable region …

Affibody molecules are small (58 amino acids) engineered scaffold proteins that can be
selected to bind to a large variety of proteins with a high affinity. Their small size and high …

The use of radiolabelled antibodies was proposed in 1970s for staging of malignant
tumours. Intensive research established chemistry for radiolabelling of proteins and …

The human epidermal growth factor receptor family (EGFR-family, other designations: HER
family, RTK Class I) is strongly linked to oncogenic transformation. Its members are …

Following the advancement of the Positron Emission Tomography (PET), a novel technique
emerged which takes advantage of the gamma quanta emitted, in some cases, after the β+ …

Recent advances in molecular characterization of tumors have made possible the
emergence of new types of cancer therapies where traditional cytotoxic drugs and …

Cobalt–sarcophagine complexes exhibit high kinetic inertness under various stringent
conditions, but there is limited literature on radiolabeling and in vivo positron emission …

This work presents the production with a cyclotron of the positron emitter 55 Co via the 54 Fe
(d, n) and 58 Ni (p, α) reactions and the Auger electron emitter 58m Co via the 57 Fe (d, n) …